Web Results

Methamphetamine use and rates of incarceration among street ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2731743/

Aug 12, 2009 ... Incarceration may be a risk factor for drug related harm among IDU, since ... high school); history of foster care (yes vs. no); history of ER use (yes vs. no); .... Agouron Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals Inc., .... Haase D, Mahaffey S, Moses S, Morin M, Patrick DM, Predy G, et al.

Presenting - Strafford

media.straffordpub.com/products/diversity-jurisdiction-and-removal-to-federal-court-2011-09-27/presentation.pdf

Sep 27, 2011 ... amount of a corporation's business activity State by State. If the amount of .... Burns v. Western Southern Life Ins. Co., 298 F.Supp.2d 401, 403 (S.D. W. Va. 2004). ..... e.g., Holmes v. Boehringer Ingelheim ..... Samura v. Kaiser Foundation Health Plan, Inc., et al., 715 ... Watson v. Blankenship 20 F 3d 383 386.

Curious Anticoagulation Cases - Medscape Education

www.medscape.org/viewarticle/846350

Sep 23, 2015 ... Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi ...

Therapeutic Class Overview Platelet Inhibitors

www.medicaid.nv.gov/Downloads/provider/Platelet inhibitors 2014 11.pdf

Sep 24, 2014 ... Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2012 Sep. 9. ... Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. ... Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al.

Consensus and Update on the Definition of On-Treatment Platelet ...

content.onlinejacc.org/pdfaccess.ashx?ResourceID=6231928&PDFSource=13

Ron Waksman, MD,*** Sunil V. Rao, MD,yyy Dimitrios Alexopoulos, MD,zzz .... Han-mi Pharmaceuticals, Boehringer-Ingelheim, Otsuka, Accumetrics, and Haemo- netics. ... fees from AstraZeneca, Merck & Co., Inc., Eli Lilly, and Daiichi Sankyo. ..... et al. (43) suggested that an individualized antiplatelet regimen based on PFT ...

Antiplatelet therapy after coronary artery stenting - UpToDate

www.uptodate.com/contents/antiplatelet-therapy-after-coronary-artery-stenting

Oct 20, 2015 ... Coronary artery stents, particularly drug-eluting stents (DES), are used in ... is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc. ... PPI]); Boehringer-Ingelheim (AF [Dabigatran]); CSL Behring (Lipids); ...... Bertrand ME, Legrand V, Boland J, et al. .... Levine GN, Bates ER, Blankenship JC, et al.

Antiplatelet Therapy Discontinuation and the Risk of Serious ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0124314

Apr 8, 2015 ... If the drug was restarted after discontinuation, the dates of restart were also recorded. ... (SAS Institute Inc., Cary, NC, USA), and Excel 2010 (Microsoft Co., Redmond, WA ..... Three vs twelve months of dual antiplatelet therapy after .... Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al.

Benefactors | WSU Foundation | Washington State University

foundation.wsu.edu/benefactors/

Corporation; AVMA Group Health & Life Insurance Trust; AVMA PLIT; Avstar; † Carolyn ... †Eugene A. Bahr and †Denice Kay (Bahr) Summers; Robert V. "Bob" Baker ... Blevins; †Luther and †Dilie Boe; Boehringer Ingelheim Pharmaceuticals, Inc ... †Kenneth Braget; Blankenship Farms; †Dorothy L. Bray; Brayton Harshman  ...

Sealed Settlement Agreements in Federal District Court - U.S. Courts

www.uscourts.gov/file/document/sealed-settlement-agreements-federal-district-court-2004

Sealed Settlement Agreements. 2 v. Cyrovac Inc., 805 F.2d 1, 11 (1st Cir. 1986); Leucadia ..... son Lumber Co. v. Cahaba Pressure-Treated Forest Products (AL-N 7:98-cv-00043 filed ... (drug-related seizure of property case resolved by consent judgment). 10. ..... 7-3 et seq. shall govern the hearing of any such application.

Audio-Digest Foundation: Written Summary: ACCEL: AC4703

www.audio-digest.org/CME-Summary/accel/AC4703/ACCEL

Mar 1, 2015 ... Although originally an “orphan drug” developed for patients with ... Recently, Thomas et al. reported on the safety and efficacy of ... Richard V. Milani, MD, and Carl J. Lavie, MD, noted that for patients with ..... Co Inc (G,B); Essentialis Inc (G); Boehringer Ingelheim GmbH (G); Automedics Medical Systems (E).

Helpful Resources

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

www.leagle.com

ANUSHAVAN G. TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. PETERS, C. J. The principal issue in this appeal is whether there was ...

In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation

www.law360.com

Boehringer Ingelheim International GmbH has agreed to pay roughly $650 million to settle claims in multidistrict ... Richard W Cohen, Lowey Dannenberg et al ..... Mamie Virginia Blankenship ... Boehringer Ingelheim Pharmaceuticals, Inc.

Dec 2015 FAQs | College of Pharmacy | University of Illinois at ...

pharmacy.uic.edu

Healey JS, Eikelboom J, Douketis J, et al. ... Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015. .... 3 vs 12. composite of cardiac death, MI, ST, TVR, or bleeding. 4.7% 12-mo vs .... Levine GN, Bates ER, Blankenship JC, et al.

PMC3324323 - National Center for Biotechnology Information

www.ncbi.nlm.nih.gov

... Elda Shipley, Coordinator, and Samantha Blankenship, MSW, Coordinator .... A study by Menza et al. suggested that nortriptyline, but not paroxetine, was .... Treatment effects (paroxetine vs placebo, venlafaxine XR vs placebo) were ..... support from Boehringer Ingelheim, Kyowa Hakko Kirin Pharma, Inc., Neurologix, Inc., ...